Is it useful to continue administration of gonadotropin releasing hormone (GnRH) agonist after embryo transfer?

A prospective randomized study evaluating the effect of administrating GnRH agonist (GnRHa) in the luteal phase on the outcome of ICSI cycles stimulated with long GnRHa protocols

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13123887

Enrollment

446

Registered

2014-02-20

Start date

2012-07-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility treated by ICSI Pregnancy and Childbirth In vitro fertilization

Interventions

The number of patients included in both groups was chosen based upon a special statistical calculation which makes the outcome of the study meaningful. After the pre-calculated number is reached the s

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women under 40 years old undergoing intracytoplasmic sperm injection (ICSI) in the first or second trial and using the long GnRHa protocol

Exclusion criteria

Exclusion criteria: 1. Donor eggs 2. Patients aged 40 or older 3. Pre-implantation Genetic Diagnosis (PGD) cycles 4. Patients with fibroids or congenital anomalies of the uterus

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate, which is measured by BhCG assay 2 weeks after embryo transfer followed by ultrasound at 6?7 weeks to detect fetal echoes and pulsation	—

Secondary

Measure	Time frame
Ongoing pregnancy rate, which is diagnosed by ultrasound examination at 20?24 weeks pregnancy to document a viable pregnancy at this point	—

Countries

Egypt

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026